Hypolipidemic and Antiobesity-Like Activity of Standardised Extract of Hypericum perforatum L. in Rats by Gulam Mohammed Husain et al.
International Scholarly Research Network
ISRN Pharmacology
Volume 2011, Article ID 505247, 7 pages
doi:10.5402/2011/505247
Research Article
HypolipidemicandAntiobesity-LikeActivity of Standardised
Extract of Hypericumperforatum L.inRats
GulamMohammed Husain,1 Shyam Sunder Chatterjee,2,3 Paras Nath Singh,1
andVikas Kumar1
1Pharmacology Research Laboratory, Department of Pharmaceutics, Institute of Technology, Banaras Hindu University,
Varanasi 221 005, India
2Pharmacology Research Laboratories, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany
3Stettiner Straße 1, 76138 Karlsruhe, Germany
Correspondence should be addressed to Vikas Kumar, vikas.phe@itbhu.ac.in
Received 31 January 2011; Accepted 13 March 2011
Academic Editor: E. E. El-Fakahany
Copyright © 2011 Gulam Mohammed Husain et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Hypericum perforatum is known to have diverse medicinal uses for centuries. The antidepressant activity of Hypericum perforatum
is widely accepted and proved in both animal and clinical studies. Present study was undertaken to investigate the eﬀect of
Hypericum perforatum in a battery of animal models for metabolic disorder. Hypericum is tested for hypolipidemic activity in
normal rats, antiobesity activity in high-fat-diet induced obese rats, and fructose-fed rats. Hypericum was orally administered as
suspension in 0.3% carboxymethyl cellulose at the doses of 100 and 200mg/kg body weight for 15 consecutive days. Hypericum
signiﬁcantly lowered total cholesterol and low-density cholesterol in normal rats. Hypericum signiﬁcantly inhibited weight gain
in high-fat-fed rats. In fructose-fed rats, Hypericum normalised the dyslipidemia induced by fructose feeding and improved the
insulin sensitivity. Taken together, Hypericum could be the antidepressant therapy of choice for patients suﬀering from comorbid
diabetes and obesity.
1.Introduction
Hypericum perforatum L. (Family: Clusiaceae), also called
St. John’s wort, is widely distributed in Europe, Asia,
North Africa, and North America. In India, Hypericum
perforatum is found in the western Himalayas at altitudes
of 3000–10,500 feet [1]. Hypericum perforatum is widely
used as complementary and alternative medicine by patients
suﬀering from a range of CNS disorders [2–7]. The antide-
pressant potential of Hypericum is widely accepted. It is
nowwellestablishedthatprolongedtreatmentwithsynthetic
antidepressant drugs markedly increased the risk of weight
gain and obesity [8]. Moreover, synthetic antidepressant
drugs are also reported to increase the risk of development of
type 2 diabetes [9]. Recently, Hypericum perforatum extract
and hyperforin, a major bioactive constituent of Hypericum
perforatum, have been reported to protect cytokine-induced
β-cell injury, thereby improving β-cell function and survival
[10] which could be potentially valuable for the prevention
or limitation of beta-cell loss, observed in diabetes. A couple
of studies from our laboratory found a signiﬁcant anti-
hyperglycemic activity of Hypericum perforatum extract in
diabetic rats [11, 12]. Therefore, we propose that Hypericum
could be the antidepressant therapy of choice for patients
suﬀering from comorbid diabetes or obesity. In view of
putative antiobesity activity, Hypericum perforatum will gain
a new perspective as an antidepressant therapy.
Animal models are useful tools for obesity research
as they readily gain weight when fed with high-fat diets
[13] .T h er a t sf e dw i t hh i g hf a td e v e l o po b e s i t y ,h y p e r -
phagia, hyperleptinemia, hyperinsulinemia, hyperglycemia,
and hypertriglyceridemia [14]. The physiological aspects of
this model replicate many of the features observed with
the human obesity syndrome [15]. Therefore, the high fat2 ISRN Pharmacology
fed model has a good translation potential to extrapolate
animal data for clinical studies. Rats, maintained on high-
fructose diet, develop an acute hypertriglyceridemia and
insulin resistance [16–18]. Fructose is more lipogenic than
glucose or starch and induces moderate obesity and several
adverse metabolic eﬀects, including hypertriglyceridemia,
hyperinsulinemia, and hypertension in rodents [19]. Fruc-
tose bypasses the phosphofructokinase regulatory step and
enters the pathway of glycolysis or gluconeogenesis at
the triose phosphate level, resulting in increased hepatic
triglyceride production [20] and insulin resistance [21].
The abnormalities and the disease progression in fructose-
fed rats resemble the human condition of metabolic syn-
dromei hence, this model also has good predictive validity.
In the present communication, hypolipidemic activity of
Hypericum perforatum was assessed in normal rats, and two
validated models were used to assess the antiobesity activity,
that is high-fat-fed model and fructose-fed model.
2.MaterialsandMethods
2.1. Animals. Adult Charles Foster rats (150 ± 10g) were
obtained from the Central Animal House of Institute of
Medical Sciences, Banaras Hindu University, Varanasi, India.
The animals were housed in groups of six in polypropylene
cages at an ambient temperature of 25 ± 1◦C and 45–
55% relative humidity, with a 12:12h light/dark cycle.
Animals were provided with commercial food pellets and
water ad libitum, except if otherwise stated. All the animals
were acclimatized to laboratory conditions for at least one
week before using them for the experiments. Principles of
laboratory animal care guidelines (NIH publication number
85–23, revised 1985) were followed. Prior approval from the
Institutional Animal Ethics Committee was obtained (Letter
no. Dean/2009-10/693).
2.2. Plant Extract. Dried hydroalcoholic (50%) extract of
whole plant of Hypericum perforatum L. was used in the
present study. Standardised extract was procured from
Indian Herbs Research and Supply Co. Ltd., Saharanpur,
India. The extract of Hypericum perforatum (HpE) was
standardised by HPLC to contain not less than 3.00%
hyperforin and 0.3% hypericinsi thus, the extract used in
the present study was similar to the extracts of Hypericum
previously studied in our laboratory [2, 4–6].
2.3. Administration of Plant Extract. HpE was suspended
in 0.3% carboxymethyl cellulose (CMC) and administered
orally through orogastric tube at the doses of 100 and
200mg/kg of body weight per day for 15 consecutive days.
Doses are selected based on the earlier studies from our
laboratory on the same extract [2, 4–6, 11].
2.4. Hypolipidemic Activity in Normal Rats. Rats were main-
tained on normal pellet diet (NPD) and orally treated
with HpE 100 and 200mg/kg for a period of 15 days.
Control group was treated with CMC throughout the 15
days of study. Cloﬁbrate 100mg/kg served as standard
hypolipidemic drug and was orally administered for 15
days [18]. Blood samples were collected on the 15th day
after appropriate fasting under ether anaesthesia, for the
estimation of total cholesterol (TC), HDL cholesterol (HDL-
C), LDL cholesterol (LDL-C), and triglyceride (TG) as in
our earlier study [12]. Total cholesterol estimation was based
on the hydrolysis of cholesterol esters by cholesterol esterase
to free cholesterol and fatty acids. The free cholesterol was
then oxidized by cholesterol oxidase to cholest-4-en-3-one
with the simultaneous production of hydrogen peroxide.
T h eh y d r o g e np e r o x i d ep r o d u c e dw a sc o u p l e dw i t h4 -
aminoantipyrine and phenol, in the presence of peroxidase,
to yield a chromogen with maximum absorbance at 505nm.
The absorbance of coloured dye was proportional to the total
cholesterol concentration present in the sample. For HDL
cholesterol estimation, LDL cholesterol, VLDL cholesterol
and chylomicron fractions were precipitated by the addition
of polyethylene glycol 6000. After centrifugation, the HDL
fraction remained in the supernatant and was analysed in
the same manner as mentioned in the total cholesterol
estimation. For triglycerides estimation, triglycerides were
hydrolysed by lipoprotein lipase to produce glycerol and
free fatty acid. In the presence of glycerol kinase and
adenosine triphosphate, glycerol was phosphorylated to
glycerol-3-phsophate and adenosine diphosphate. Glycerol-
3-phosphate was further oxidised by glycerol-3-phosphate
oxidase to yield dihydroxyacetone phosphate and H2O2.
H2O2 was then coupled with 4-aminoantipyrine and 4-
chlorophenol in the presence of peroxidase to produce red
quinoneimine dye. The absorbance of coloured dye was
measured at 505nm and was proportional to triglycerides
concentration present in the sample. LDL cholesterol was
calculated using Friedewald’s equation [22].
2.5. Fructose-Induced Hypertriglyceridemia and Insulin Resis-
tance. Rats were maintained on normal pellet diet (NPD)
and 20% fructose in drinking water for 15 days [16–18].
Control rats were given NPD and normal drinking water
throughout the study period. Rats were randomly divided
into diﬀerent groups as follows:
Group-I:NPD+normaldrinkingwater+0.3%CMC
(16th to 30th day),
Group-II: NPD + 20% fructose water + 0.3% CMC
(16th to 30th day),
Group-III: NPD + normal drinking water + 0.3%
HpE 100mg/kg (16th to 30th day),
Group-IV: NPD + normal drinking water + HpE
200mg/kg (16th to 30th day),
Group-V: NPD + 20% fructose water + HpE
100mg/kg (16th to 30th day),
Group-VI: NPD + 20% fructose water + HpE
200mg/kg (16th to 30th day).
The administration of herbal extract was started from the
16th day and was continued up to the 30th day of exper-
iment. Group-I (normal control) and Group-II (fructose
control) rats were given equal volume of vehicle (0.3% CMCISRN Pharmacology 3
suspension) for the same duration. The body weight of rats
was recorded on the 1st day and subsequently once a week,
likewise food and water intake was also recorded on a weekly
basis [18]. Blood samples were withdrawn from retroorbital
venous plexus on the 30th day after appropriate fasting,
and plasma TC, HDL-C, LDL-C, TG, and glucose were
estimated using biochemical kits. Glucose was estimated by
glucose oxidase/peroxidase method as in our earlier studies
[11, 12]. Brieﬂy, glucose was converted to gluconic acid and
H2O2 in the presence of glucose oxidase. Subsequently, in
a peroxidase-catalysed reaction, the oxygen liberated was
accepted by the chromogen system to give a red-coloured
quinine-imine compound. The absorbance of red colour
was measured at 505nm and was directly proportional to
glucose concentration. Plasma insulin level was estimated
using enzyme-linked immunosorbent assay (ELISA kit; DRG
Diagnostics, GmbH, Germany).
2.6. High-Fat-Diet-Induced Obesity. Rats were maintained
on an NPD for one week before the start of experiment.
Afteroneweek,ratswererandomlyassignedintonormaland
obese groups and fed with NPD and HFD, respectively, for
15 days. High-fat diet was made as described by Srinivasan et
al. [23]. After 15 days, the HFD-fed rats showing signiﬁcant
weight gain compared to the NPD rats were again divided
into three groups (six rats in each group): the HFD control
group fed with HFD only, the HFD + HpE (100mg/kg)
group, and the HFD + HpE (200mg/kg) group. HpE treat-
ment was started from the 16th day up to day 30. Control
group rats were provided with NPD for the entire 30 days
of study. Control group and HFD control group were given
equal volume of 0.3% CMC suspension from the 16th to the
30th day.
The body weight was recorded on day one and then on
a weekly basis. Average food intake was recorded on the 1st,
15th, and the 30th day. Fasting blood samples were collected
o n3 0 t hd a yf r o mt h er e t r o - o r b i t a lv e n o u sp l e x u su n d e r
light ether anesthesia. Plasma glucose, insulin, TC, LDL-C,
HDL-C, and TG level were estimated. On the 30th day, after
the collection of blood sample, animals were sacriﬁced and
mesenteric, perirenal, and epididymal fat pads were isolated
and weighed [24].
2.7. Statistical Analysis. Data was expressed as mean ±
standard error of mean (SEM) for each group (n = 6).
Statistical analysis was performed by one-way analysis of
variance (ANOVA) followed by the Student-Newman-Keuls
test. GraphPad InStat (version 3.06) software was used for
statistical analysis.
3. Results
3.1. Hypolipidemic Activity in Rats. 15 days of oral adminis-
tration with HpE resulted in signiﬁcant decrease of plasma
total cholesterol (F(3,20) = 19.69; P<. 001) and LDL-C
level compared to vehicle-treated control group. Cloﬁbrate
treatment decreased total cholesterol, LDL-C (F(3,20) =
18.56; P<. 001), and triglyceride with simultaneous increase
in HDL-C compared to control group (F(3,20) = 10.37;
P<. 001). Results are summarised in Table 1. There was no
statistically signiﬁcant diﬀerence in body weight of diﬀerent
treatment group throughout the study (data not shown).
3.2. Fructose-Induced Hypertriglyceridemia and
Insulin Resistance in Rats
3.2.1. Blood Glucose and Insulin Level in Fructose-Fed Rats.
HpE administration in rats maintained on normal pellet
diet and normal drinking water did not signiﬁcantly change
plasma glucose or insulin level compared to vehicle-treated
normal control rats. Fructose-fed rats showed a marked
increase in plasma glucose level along with a signiﬁcant
increase in plasma insulin level compared to vehicle-treated
normal control rats. Both doses of HpE signiﬁcantly inhib-
itedtheincreaseinplasmaglucosecausedbyfructosefeeding
(F(5,30) = 54.11; P<. 001). HpE 200mg/kg signiﬁcantly
decreased plasma insulin level compared to fructose-fed
control group (F(5,30) = 60.39; P<. 001). Results are
presented in Table 2.
3.2.2. Eﬀect of HpE on Lipid Parameters in Fructose-Fed
Rats. Fructose feeding to rats resulted in impairment in
normal lipid proﬁle leading to increased total cholesterol,
LDL-C, and triglyceride level while HDL-C was decreased.
Triglyceride level of fructose-fed rats increased up to 3
times higher than vehicle-treated normal rats. HpE dose
dependently and signiﬁcantly decreased total cholesterol
(F(3,20) = 13.05; P<. 01) and TG level (F(3,20) = 77.06;
P<. 001) while HDL-C was increased compared to vehicle-
treated fructose fed rats (F(3,20) = 10.66; P<. 01). Results
are summarized in Table 3.
3.2.3. Eﬀect of HpE on Body Weight in Fructose-Fed Rats.
Fructose-fed rats signiﬁcantly gained weight compared to
normal rats (F(5,30) = 8.18; P<. 001). The oral
administration of HpE for 15 days did not alter the body
weight of rats compared to vehicle-treated control rats.
HpE administration reduced body weight gain induced
by fructose feeding; however, data remained statistically
insigniﬁcant (Table 2).
3.3. High-Fat-Diet-Induced Obesity
3.3.1. Eﬀect of HpE on Body Weight and Food Intake in
HFD-Induced Obese Rats. There was no signiﬁcant diﬀer-
ence in body weight of diﬀerent treatment groups at the
commencement of study. Animals fed with high-fat diet
showed signiﬁcant increase in body weight compared to
those fed with NPD. HpE dose dependently and signiﬁcantly
inhibited the increase in body weight induced by high-
fat diet (F(3,20) = 61.21; P<. 001). On day 30, there
was no statistically signiﬁcant diﬀerence in body weight of
200mg/kg HpE-treated HFD-fed rats and NPD control rats
(Figure 1). The average daily food intake of all the groups
was the same at the commencement of study; however, 154 ISRN Pharmacology
Table 1: Eﬀect on Hypericum perforatum and cloﬁbrate on plasma lipid parameters in normal rats.
Group (n = 6) Total-C (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) Triglyceride (mg/dL)
Control (CMC) 83.98 ± 1.34 31.89 ± 1.21 41.46 ± 2.21 53.10 ± 2.49
HpE 100mg/kg 73.29 ± 2.10∗∗ 35.24 ± 1.56 29.02 ± 2.73∗ 45.11 ± 2.70
HpE 200mg/kg 70.51 ± 1.61∗∗ 36.64 ± 1.42 25.20 ± 1.60∗∗ 43.33 ± 3.67
Cloﬁbrate 100mg/kg 64.96 ± 2.04∗∗ 42.19 ± 1.09∗∗ 15.17 ± 3.25∗∗ 38.00 ± 2.14∗
∗P<. 01, ∗∗P<. 001 versus Control group.
Table 2: Eﬀect of Hypericum perforatum on plasma glucose, insulin, and body weight gain in fructose-fed rats.
Group (n = 6) Glucose (mg/dL) Plasma insulin (μIU/mL) Body weight gain (g)
Normal control
(normal drinking water + CMC) 80.52 ± 3.44 18.05 ± 0.79 12.33 ± 1.05
Fructose control (fructose + CMC) 149.66 ± 4.49∗∗ 35.03 ± 1.24∗∗ 26.83 ± 2.59∗∗
Normal drinking water + HpE 100mg/kg 82.53 ± 3.35†† 19.37± 0.95†† 11.50 ± 1.48††
Normal drinking water + HpE 200mg/kg 78.18 ± 1.71†† 20.29 ± 0.78†† 11.83 ± 1.30††
Fructose + HpE 100mg/kg 125.44 ± 5.70∗∗† 32.32 ± 1.10∗∗ 21.00 ± 3.62∗
Fructose + HpE 200mg/kg 105.15 ± 3.88∗∗†† 30.58 ± 0.83∗∗† 20.17 ± 2.17∗
∗P<. 05, ∗∗P<. 001 versus normal control; †P<. 01, ††P<. 001 versus fructose control.
Figure 1: Eﬀect of Hypericum perforatum on body weight changes
in high-fat-induced obese rats.
days feeding with high-fat diet signiﬁcantly increased the
average food intake on the 15th day. Treatment with HpE
signiﬁcantly reduced the food intake on day 30 compared to
the HFD control group (F(3,20) = 25.97; P<. 001). Results
are depicted in Figure 2.
3.3.2. Eﬀect of HpE on Lipid Parameters in HFD-Induced
Obese Rats. Animals of HFD control groups showed a
signiﬁcant increase in plasma total cholesterol, LDL-C, and
triglyceride level while plasma HDL-C was signiﬁcantly
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Figure 2: Eﬀect of Hypericum perforatum on average daily food
intake in high-fat-induced obese rats.
decreased compared to NPD control animals. Both doses of
HpE signiﬁcantly reduced TC (F(3,20) = 37.51; P<. 001),
LDL-C (F(3,20) = 55.68; P<. 001), and TG (F(3,20) =
37.50; P<. 01) level while HDL-C was increased signiﬁcantly
(F(3,20) = 22.33; P<. 05). Results are presented in
Table 4.
3.3.3. Eﬀect of HpE on Blood Glucose and Insulin in HFD-
Induced Obese Rats. HFD fed-rats showed a moderate
but signiﬁcant increase in plasma glucose level (averageISRN Pharmacology 5
Table 3: Eﬀect on Hypericum perforatum on plasma lipid parameters in fructose-fed rats.
Group (n = 6) Total-C (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) Triglyceride (mg/dL)
Normal control
(normal drinking water + CMC) 81.68 ± 2.36 36.21 ± 1.41 35.98 ± 1.65 47.48 ± 3.15
Fructose control (fructose + CMC) 117.12 ± 5.12∗∗∗ 27.38 ± 1.35∗∗∗ 62.04 ± 4.89∗∗ 138.52 ± 4.88∗∗∗
Fructose + HpE 100mg/kg 106.01 ± 4.35∗∗ 30.12 ± 0.92∗∗ 57.25 ± 5.57∗∗ 93.24 ± 4.12∗∗∗††
Fructose + HpE 200mg/kg 96.99 ± 4.25∗† 33.69 ± 1.01† 47.21 ± 4.84 80.50 ± 4.80∗∗∗††
∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 versus normal control; †P<. 01, ††P<. 001 versus fructose control.
Table 4: Eﬀect of Hypericum perforatum on plasma lipid parameters in high-fat-induced obese rats.
Group (n = 6) Total-C (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) Triglyceride (mg/dL)
Normal control (NPD + CMC) 53.60 ± 2.27 34.65 ± 0.92 33.55 ± 3.07 53.60 ± 2.27
HFD control (HFD + CMC) 105.03 ± 4.87∗∗ 24.62 ± 0.79∗∗ 116.49 ± 6.68∗∗ 105.03 ± 4.87∗∗
HFD + HpE 100mg/kg 86.27 ± 2.51∗∗†† 28.24 ± 0.89∗∗† 80.72 ± 3.83∗∗††† 86.27 ± 2.51∗∗††
HFD + HpE 200mg/kg 80.42 ± 3.61∗∗††† 30.19 ± 0.93∗††† 62.85 ± 4.21∗∗††† 80.40 ± 3.61∗∗†††
∗P<. 01, ∗∗P<. 001 versus normal control; †P<. 05, ††P<. 01, †††P<. 001 versus HFD control.
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Figure 3:EﬀectofHypericum perforatum onvariousadiposetissues
in high-fat-induced obese rats.
plasma glucose level = 130mg/dL) a long with a signiﬁcant
increase in plasma insulin level compared to vehicle-treated
normal control rats. HpE dose dependently and signiﬁcantly
inhibited the increase in plasma glucose caused by high-fat
diet (F(3,20) = 34.01; P<. 001) along with a simultaneous
decrease in plasma insulin level (F(3,20) = 88.02; P<. 001)
compared to vehicle-treated HFD control group (Table 5).
3.3.4. Eﬀect of HpE on Adipose Tissue in HFD-Induced Obese
Rats. Figure 3 demonstrates the eﬀect of various treatments
on mesenteric, perirenal, and epididymal fat pads. There was
a signiﬁcant increase in total adipose tissue in HFD control
group compared to NPD control rats. HpE signiﬁcantly
inhibited the accumulation of body fat in mesenteric and
perirenal regions compared to vehicle-treated HFD control
rats (F(3,20) = 76.78; P<. 001). However, total adipose
Table 5: Eﬀect of Hypericum perforatum on plasma glucose and
insulin in high-fat-induced obese rats.
Group (n = 6) Glucose (mg/dL) Plasma insulin
(μIU/mL)
Normal control
(NPD + CMC) 84.96 ± 3.58 16.61 ± 0.86
HFD control
(HFD + CMC) 130.89 ± 3.70∗∗ 62.14 ± 2.95∗∗
HFD + HpE
100mg/kg 112.15 ± 3.08∗∗† 36.47 ± 2.25∗∗†
HFD + HpE
200mg/kg 98.89 ± 3.01∗† 28.78 ± 1.53∗∗†
∗P<. 01, ∗∗P<. 001 versus normal control; †P<. 001 versus HFD control.
tissue contents of all HFD groups were signiﬁcantly higher
than NPD control rats.
4. Discussion
In our study, 15 days of repeated oral administration of
Hypericum perforatum extract and cloﬁbrate have shown a
signiﬁcant hypolipidemic activity in normal rats. Elevated
plasma lipoprotein level, especially hypercholesterolemia,
results from increased absorption of cholesterol from the
intestine or enhanced endogenous synthesis [25]. Therefore,
there could be two possible underlying mechanisms of
observed hypolipidemic activity of plant extracts, that is, the
blockade of biosynthesis of cholesterol or decrease in dietary
cholesterolabsorptionfromtheintestinebybindingwithbile
acids within the intestine and increasing bile acids excretion.
Inthepresentstudy,HpEnotonlyshowedhypolipidemic
activity in normal rats but also normalised the lipid abnor-
malities induced by HFD or fructose feeding. Eﬀects of HpE
on lipid parameters are consonant with the earlier ﬁnding
of Laggner et al. [26]. HpE also signiﬁcantly reduced the6 ISRN Pharmacology
increased plasma glucose level in fructose or HFD-fed rats
indicating improvement in insulin functions. Thus, reversal
of fructose-induced insulin resistance appears to be the likely
mechanism responsible for the observed eﬀects of HpE on
lipid parameters.
HpE showed signiﬁcant inhibition in weight gain
induced by high-fat diet or fructose feeding. Serotonin is
important neurotransmitter that controls increase in body
massandisinvolvedinthepathophysiologyofobesityaswell
asdepression[27].Serotoninreleaseisincreaseduponintake
of carbohydrates. Serotonin regulates the overconsumption
of carbohydrate-rich foods. Serotonin has also been reported
to decrease food intake in fructose-fed rats [28]. Hypericum
perforatum increases the quantity of serotonin present
within synaptosomes by inhibiting synaptosomal uptake of
serotonin [29]. This increased level of serotonin caused by
HpE reduces the food intake and suppresses the appetite
[30, 31]. Thus increased serotonergic transmission might be
theconnectinglinkbetweenantidepressant-andantiobesity-
like activity of HpE.
5. Conclusion
The present study demonstrates that HpE decreases body
weight gain, serum parameters (total cholesterol, LDL-
C, triglyceride, glucose, insulin) and increases HDL-C in
fructose and HFD-fed rats. Taken together, Hypericum could
be the antidepressant therapy of choice for patients suﬀering
from comorbid diabetes and obesity.
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